Dysmenorrhea Treatment Market: Top Companies, Business Growth & Investment Opportunities, Share, Segments and Forecast to 2027
Dysmenorrhea Treatment Market - Overview
Dysmenorrhea refers to the painful menstruation women
experience during their monthly discharging periods. While it is normal for women to have mild
abdominal cramps on the initial days of their menstruation, about 30% of women
experience severe pain along with headaches and nausea that could be termed as
Dysmenorrhea. Over the past decade, the prevalence of Dysmenorrhea is observed
to be growing. Reasons could be environmental changes, change in diet, and lack
of nutritious diet, etc.
Acknowledging the exponential growth the market perceives
currently; Market Research Future (MRFR), in its recently published market
forecast asserts that the global Dysmenorrhea
Treatment Market will reach USD 8.40 Bn. by 2023, registering a
striking CAGR of 12.28% throughout the forecast period (2017 – 2023). In 2016,
the market had valued at USD 5.68 Bn.
MRFR recognizes the following companies as the key
players in the global dysmenorrhea treatment market— Johnson & Johnson
(US), GlaxoSmithKline PLC (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bayer
AG (Germany), Focus Consumer Healthcare, LLC (US), Novartis AG (Switzerland),
Pfizer, Inc. (US), Reckitt Benckiser Group plc. (UK), Sanofi S.A. (France) and
Viatris Inc. (US) among others.
Dysmenorrhea Treatment Market - Segmentations
MRFR has segmented the report into three key dynamics for an
easy grasp and enhanced understanding: -
By Type :
Primary and Secondary (Adenomyosis, Endometriosis, Uterine myomas, Cervical
stenosis, Endometrial polyps, and Obstructive malformations of genital tract.).
By Treatment: Non-Steroidal Anti-Inflammatory Drugs
(Nsaids), Hormonal, and Combined Oral Contraceptive among others.
By End-User: Hospitals, Clinics, Diagnostic Centers,
and Pharmaceutical Companies among Others.
By Regions:
North America, Europe, APAC and Rest of the World.
Global Dysmenorrhea Treatment Market - Regional Analysis
Globally North America leads the dysmenorrhea
in adolescent with the significant market share. The Market is expected
to grow phenomenally from 2017 to 2023. Attributing to the favorable
reimbursement scenario and higher expenditure on healthcare the market is
expected to perceive a healthy growth.
The factor contributing to the market growth include
increasing prevalence of issues and disorders associated with women’s
reproductive system fuelled by the changing lifestyle and growing awareness
towards the availability of the treatments. The US, backed by the technological
advances and availability of funding for the development of new therapeutics
and treatment accounts for the major contributor to the market growth.
Europe emerging as a lucrative market for Dysmenorrhea
Treatment will expand registering a phenomenal CAGR. The resurging economy in the region is
expected to foster the regional market growth, increasing per capita healthcare
expenditures. The financial support provided by private and governments bodies
for R&D activities and new improved reimbursement policies in healthcare
will fuel the Dysmenorrhea Treatment market in Europe.
Global Dysmenorrhea Treatment Market - Competitive Landscape
The competitive market for Dysmenorrhea Treatment is
fragmented with many large and small players operating in the market. Market
players incorporate acquisition, collaboration, expansion, technology launch
and strategic partnership. These players substantially invest in R&D and
clinical trials to develop effective drugs.
To help accelerate pharmaceutical innovations and to gain a
better understanding of the conditions, these pharma companies collaborate with
academia and the biotech industry partners who can contribute cutting-edge
technologies and specialized knowledge.
These collaborations are one of the innovation strategies of
market players. Companies can leverage the latest scientific knowledge and
translate it into innovative medicines through partnering. These partnerships
can kindle the innovative impulses that advance medicine and benefit patients
as well as partners.
Industry/Innovation/ Related News:
January 04, 2018 – Pfizer Inc. (US) a pharmaceutical
conglomerate announced the partnership with 23andMe (US), a privately held
personal genomics and biotechnology company to aid understanding of depression,
dysmenorrhea and the genetic heterogeneity of lupus and inflammatory bowel
disease. Pfizer believes that such collaborations will help it to potentially
usher in a new era of patient care defined by targeted research methods and
ultimately better patient outcomes.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment